ArticleJournal of traditional and complementary medicine2026
ZishenWan reduces obesity in
Article in Journal of traditional and complementary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Obesity is a major risk factor for metabolic disorders, including type 2 diabetes, metabolic syndrome, and cardiovascular diseases. Recent studies suggest that adipocyte cell cycle regulation is linked to metabolic dysfunction, making cell cycle regulatory factors potential therapeutic targets. ZishenWan (ZSW), a traditional Chinese medicinal formula composed of three herbs, has shown therapeutic potential against diabetes and obesity. This study aimed to investigate the mechanisms underlying the weight-regulatory effects of ZSW. Methods: ZSW was orally administered to Results: ZSW significantly reduced body weight, inhibited adipocyte hypertrophy, and improved insulin sensitivity and insulin secretion in Conclusions: ZSW may improve obesity-related metabolic disorders by activating the PI3K/AKT pathway and downregulating p21 expression in EAT. These effects promote adipocyte apoptosis, enhance thermogenesis, inhibit adipocyte hypertrophy, and improve insulin sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.